Indole compounds produced by gut microbiota after metabolizing tryptophan improve dysmotility in sepsis via the AHR-TRPA1 axis in enteric nerves Authors: Jintao Zhang, Ziang Li, Tong Jin, Wanglin Zhang, Hongwei Shi, Kanlirong Wang, Jiayi Qi, Liqun Sun Published: 2025 ABSTRACT AbstractBackgroundSepsis represents a major global health challenge, and the resulting impaired intestinal motility can lead to numerous adverse outcomes. Indole compounds produced by gut microbiota after metabolizing tryptophan may improve sepsis-induced intestinal dysmotility, though the underlying mechanism remains unclear. Here, we explored the role of 6-formylindolo[3,2-b]carbazole (FICZ), a gut-derived metabolite of tryptophan, in improving dysmotility in sepsis. We found that FICZ-activated aryl hydrocarbon receptor (AHR) on the Enteric Nervous System (ENS) may represent a future therapeutic target for treating dysmotility in sepsis.MethodsFive days post-fertilization (5dpf) zebrafish underwent intraperitoneal microinjection of Escherichia coli to induce sepsis. Subsequently, zebrafish were treated with varying concentrations of FICZ and Tol-huc-AHR1a overexpression plasmids. Primary methodologies included micro-filming for intestinal motility observation, immunofluorescence for detecting intestinal motility function-related indicators, and PCR for gene-level analysis. Key endpoints included intestinal peristalsis frequency, neutrophil infiltration, smooth muscle contractility, NO levels, and expression levels of AHR1a, AHR2, TRPA1b, and relevant inflammatory genes.ResultsIn septic zebrafish, FICZ reduced intestinal neutrophil infiltration, restored intestinal smooth muscle strength, increased intestinal peristalsis frequency, and enhanced the expression of intestinal AHR1a, AHR2, and transient receptor potential ankyrin 1b(TRPA1b) genes. Overexpression of the AHR1a gene in septic zebrafish reduced the production of the inhibitory neurotransmitter NO by restoring TRPA1b expression in the intestine, thereby restoring intestinal motility. It also restored the low expression level of inflammatory genes in immunocompromised septic zebrafish.ConclusionThe gut microbial metabolite indole improved sepsis-induced intestinal dysmotility via the AHR-TRPA1 axis. AHR may be a future therapeutic target for treating the immunosuppressive state associated with sepsis.Keywords: Sepsis; Intestinal dysmotility; Aryl hydrocarbon receptor; Transient receptor potential ankyrin 1; 6-formylindolo[3,2-b]carbazole Background Sepsis is defined as a type of life-threatening organ dysfunction caused by dysregulated host responses to infections [1]. The high mortality rate of sepsis poses a major challenge in intensive care units. The gut plays a central role in the progression of sepsis and multiple organ dysfunction [2, 3]. Clinically, imaging studies revealed significantly reduced intestinal motility in patients with sepsis, manifesting as intestinal dysmotility and even intestinal obstruction in severe cases. This phenomenon has also been validated in animal models of sepsis [4, 5]. Factors such as impaired intestinal blood flow, intestinal barrier damage, and gut dysbiosis all contribute to intestinal motility disorders in sepsis [6, 7]. Recently, with the advancement of research, it has been discovered that the gut microbiota play a crucial role in intestinal failure subsequent to sepsis [8]. Gut microbiota and their metabolites affect the development of sepsis-related diseases through various mechanisms [9]. In our preliminary study, we collected stool samples from patients with sepsis within 24 h of admission to conduct targeted metabolomics analysis of gut microbiota metabolites. We found that indoleacetaldehyde levels decreased most significantly in the stool of patients with sepsis [10]. Combined with the phenomenon of intestinal motility disorders observed in hospitalized sepsis patients and animal models of sepsis, the reduced levels of the gut microbiota metabolite indoleacetaldehyde may be a reason behind intestinal motility disorders in sepsis. 3-Indoleacetaldehyde is a product of tryptophan metabolism by gut microbiota and serves as a ligand for the aryl hydrocarbon receptor (AHR). It has been shown to improve depression or mild cognitive impairment via the brain-gut axis [11, 12]. AHR belongs to the basic helix-loop-helix (BHLH)-PAS transcription factor family and functions as an evolutionarily conserved environmental sensor [13]. In humans and animals, AHR ligands primarily originate from dietary indoles and several metabolites of tryptophan produced by gut microbiota, such as 3-indoleacetaldehyde, 3-indolepyruvate, 3-indolecarboxaldehyde, 3-methylindole, 3-indoleacetaldehyde, 3-indolepyruvate, and tryptamine [14]. After binding to its ligand, AHR translocates into the nucleus, dimerizes with its chaperone protein AHR nuclear translocation protein (NTLP), and regulates the expression of target genes after binding to the xenobiotic response element (XRE) [15]. Studies have reported the presence of AHR receptors in the longitudinal muscle myenteric plexus (LMMP) of mouse colon, whose expression levels were found to be correlated with gut microbial load. AHR gene knockout in intestinal myenteric neurons reduced colonic motility in mice [16], suggesting that reduced AHR expression in LMMP subsequent to decreased indoleacetaldehyde levels may underlie dysmotility in sepsis. TRPA1 is a transient receptor potential ankyrin 1, a calcium-permeable non-selective cation channel located on the cell membrane [17]. TRPA1 is expressed in gastrointestinal neurons and mucosal epithelial cells, primarily distributed in myenteric neurons and colocalized with nitric oxide synthase-producing neurons. It affects intestinal motility by modulating the production of NO, an inhibitory neurotransmitter in the gut [18]. Given that AHR and TRPA1 on enteric neurons affect intestinal motility, we hypothesized that sepsis-associated dysmotility may occur due to reduced indoleacetaldehyde levels and suppression of AHR expression or activation. This, in turn, affects TRPA1 expression and function, upregulating NO levels and resulting in intestinal dysmotility. We employed zebrafish as our experimental model to investigate the mechanism by which reduced indoleacetaldehyde levels in gut microbiota metabolites cause intestinal dysmotility in sepsis. Using zebrafish to study the mechanisms underlying sepsis-induced intestinal dysmotility offers the following advantages: (1) Zebrafish exhibit significant physiological similarity and functional conservation compared to humans, with at least one clear zebrafish ortholog for 70% of human genes; (2) Zebrafish embryo manipulation and whole-body imaging are relatively straightforward; (3) High fecundity, low cost, and body transparency allow direct microscopic observation of intestinal motility, making zebrafish suitable for studying the mechanisms underlying motility dysfunction; (4) Forward-reverse genetics and genome editing are more readily achievable in zebrafish than in mammals [19–21]. Materials and methods Establishment of a zebrafish model for sepsis The zebrafish used were provided by Hunter Biotechnology, Inc (Hangzhou, China) and maintained in aquarium water at 28 °C (water composition: 200 mg of instant marine salt added per liter of reverse osmosis water, conductivity 450–550 µS/cm; pH 6.5–8.5; hardness 50–100 mg/L CaCO₃). Inoculate E.coli (Guangdong, China) into LB medium and incubate at 37 °C with shaking at 200–250 rpm for 12–16h to obtain a high-density stock culture. Measure the OD600 of the stock culture to determine its concentration. Dilute to the working concentration required for subsequent experiments. Re-measure the OD600 of the working solution to verify the concentration of the resulting E.coli suspension. E.coli suspensions were microinjected into the peritoneal cavity of 5-day-post-fertilization (5 dpf) zebrafish at a volume of 10.0 nL per fish. Each zebrafish in the control group also received a 10.0 nl intraperitoneal microinjection of sterile PBS. Modeled zebrafish were randomly assigned to 6-well plates containing 3 mL per well, with 30 fish per treatment group and a control group. Relevant parameters were assessed after 6 and 48 h at 28 °C. Construction of pan-neuronal AHR1a-overexpression zebrafish Randomly selected zebrafish embryos at the single-cell stage from different strains were injected with a mixture of the Tol-huc-AHR1a overexpression plasmid and TP transposase (final injection concentration: 25.0 ng/µL) to generate zebrafish overexpressing the pan-neuronal AHR1a gene. These embryos were used for subsequent experiments at 5 days post-fertilization (5 dpf). FICZ maximum tolerated concentration test (MTC) Wild-type AB strain zebrafish at 5 dpf were used. A control group was established. Zebrafish were randomly assigned to 6-well plates, with each well holding 3 mL of solution. Each well (experimental group) contained 30 treated zebrafish. Each well received FICZ (Sigma, USA) at concentrations of 3.91 µM, 7.81 µM, 15.6 µM, 31.2 µM, and 62.5 µM, with a control group included. After 48 h of treatment at 28 °C, the condition and survival rate of the zebrafish were observed. Detection of neutrophil infiltration in the intestine Using 5 dpf Tg(mpx: EGFP) zebrafish (HuanTe, China), neutrophils in this strain exhibit green fluorescence under fluorescence microscopy. Six hours after sepsis modelling, zebrafish were photographed under fluorescence microscopy. Data were acquired using NIS-Elements D 3.20 advanced image processing software to analyze neutrophil counts in specific regions of the zebrafish intestine. Intestinal smooth muscle strength testing Using 5 dpf Tg(acta2:mCherry) zebrafish (HuanTe, China), the smooth muscle within this zebrafish strain emits red fluorescence under fluorescence microscopy. Forty-eight hours after sepsis modelling, zebrafish were photographed under fluorescence microscopy. Data were acquired using NIS-Elements D 3.20 advanced image processing software to analyse fluorescence intensity in intestinal smooth muscle. Intestinal peristalsis monitoring Wild-type AB strain zebrafish at 5 dpf were used for sepsis modeling. After 48 h, zebrafish were placed under a fluorescence microscope to record a 2-minute video of intestinal peristalsis. A complete wave from the foregut to the hindgut was counted as one valid intestinal peristaltic event. The number of intestinal peristaltic events within the 2-minute video was statistically determined. Intestinal smooth muscle strength testing Using 5 dpf smooth muscle red fluorescent strain zebrafish for sepsis modeling, images were captured under a fluorescence microscope 48 h post-modeling. Data were acquired using NIS-Elements D 3.20 advanced image processing software to analyze the fluorescence intensity of intestinal smooth muscle in zebrafish. Intestinal nitric oxygen (NO) levels testing Wild-type AB strain zebrafish were used to model sepsis. After 48 h, the fish were stained with an NO fluorescent probe (Thermo Fisher Scientific, USA) in the dark for 1.5 h. Following three washes with standard dilution water, the zebrafish were photographed under a fluorescence microscope. Data were acquired using NIS-Elements D 3.20 advanced image processing software to analyze NO fluorescence intensity in the zebrafish intestine. Intestinal pathology tissue section The euthanasia procedure for zebrafish is as follows: Place the zebrafish rapidly into a solution of MS-222 (Tricaine Methanesulfonate) at a concentration of 400 mg/L, with the pH adjusted to 7.0–7.4 using sodium bicarbonate; Once gill cover movement and all spontaneous bodily activity have ceased completely, continue immersion for a further 10 min. Subsequently, promptly place the zebrafish in a −80 °C freezer for two hour to ensure complete death. After euthanizing zebrafish, they were fixed in formalin solution, dehydrated with alcohol, and cleared with xylene before being embedded in paraffin. Following sectioning and mounting, sections were stained with hematoxylin and eosin (H&E). Finally, slides were sealed with neutral resin and examined under a microscope for analysis. Gene expression detection Total RNA was extracted from zebrafish intestines of each group using an RNA extraction kit (Thermo Fisher Scientific, USA). Total RNA concentration and purity were determined using a UV-visible spectrophotometer. Take 2.00 µg of zebrafish intestinal total RNA and synthesize 20.0 µL cDNA according to the instructions of the cDNA First Strand Synthesis Kit (Thermo Fisher Scientific, USA). Primers were designed using the Primer-BLAST tool from NCBI. The generated primers were then aligned against the corresponding gene nucleotide sequences using SnapGene software to ensure binding specificity. Quantitative PCR (q-PCR) was performed using the Universal SYBR qPCR Master Mix (Vazyme, China) kit under the following cycling conditions: 3 min pre-denaturation at 95 °C, followed by 40 cycles (each cycle comprising 10 s denaturation at 95 °C and 30 s annealing/extension at 60 °C). All primers employed in this study exhibited efficiency ranging from 92% to 109%, with correlation coefficients (R²) between 0.98 and 0.99 for dilution series. Fluorescence signals were monitored within the 65 °C to 95 °C range, confirming the presence of a single, sharp melting peak in the melting curve analysis. Subsequently, β-actin served as the internal control for gene expression, and the relative RNA expression levels of the AHR1a, AHR2, CYP1a, TRPA1b, IL-6, IL-1β, and TNF-α genes were quantified using the 2^(△△Ct) method. The primers for the relevant genes are as follows: GenePrimer sequence β-actinForward5’-TCGAGCAGGAGATGGGAACC-3’Reverse5’-CTCGTGGATACCGCAAGATTC-3’ AHR1aForward5’-CGCAAAAGGAGGAAACCTGTC-3’Reverse5’-CCTGTAGCAAAAATTCCCCCT-3’ AHR2Forward5’-TGGACTAGATCAGACAACCC-3’Reverse5’-GAAGAGGGAGAGTCATTGTG-3’ CYP1aForward5’-AGGACAACATCAGAGACATCACCG-3’Reverse5’-GATAGACAACCGCCCAGGACAGAG-3’ TRPA1bForward5’-CTCATTTGTCTTGGAAAGGGAGC-3’Reverse5’-GGAGGAAGTTGCGACCTGTT-3’ IL-6Forward5’-TCAACTTCTCCAGCGTGATG-3’Reverse5’-TCTTTCCCTCTTTTCCTCCTG-3’ IL-1βForward5’-GAACAGAATGAAGCACATCAAACC-3’Reverse5’-ACGGCACTGAATCCACCAC-3’ TNF-αForward5’-GCGCTTTTCTGAATCCTACG-3’Reverse5’-TGCCCAGTCTGTCTCCTTCT-3’ Statistical analyses The n values represent individual zebrafish for in vivo experiments and biological replicates in cell line and organoids. Unless otherwise stated, all statistical analyses were carried out through two-sided unpaired t tests, 1-way ANOVA, or 2-way ANOVA followed by either Tukey’s or Sidak’s multiple comparison tests, as appropriate. Data were considered statistically significant when p < 0.05. Results Establishment of a zebrafish sepsis model Zebrafish exhibit certain consistencies with mouse models in terms of immune responses, cytokine secretion, inflammatory reactions, and organ dysfunction. For instance, inflammatory responses in Zebrafish are characterized by similar upregulation of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) [22]. The methods currently used for establishing a zebrafish model of sepsis primarily include: (1) LPS water bath. Immersion of zebrafish in LPS-containing solutions can induce vascular damage and leakage, caudal fin edema, and immune activation. However, this inflammation originates at the epithelial surface and is not conducive to LPS detoxification and subsequent resolution of inflammation; thus, it does not fully mimic the common clinical state of sepsis [23]; (2) Microscopic injection of LPS into zebrafish embryos or circulation [24]. In this approach, zebrafish exhibit immune responses and organ dysfunction similar to those seen in inflammatory states. However, studies have indicated LPS tolerance in zebrafish, demonstrating high resistance to LPS [25]. To establish a zebrafish model more closely mimicking the clinical state of sepsis, we established a sepsis model by microinjecting Escherichia coli(E.coli) into the peritoneal cavity of zebrafish. Each zebrafish was microinjected intraperitoneally with a suspension containing 1 × 10² to 1 × 10⁶ CFU of E.coli. The mortality rates were recorded after 48 h. The results revealed that mortality began occurring at 1 × 10⁴ CFU/fish, with a mortality rate of 33% (10/30). Mortality rates progressively increased after injecting higher doses of E.coli, reaching 73% (22/30) at 1 × 10⁵ CFU/fish and 96% (29/30) at 1 × 10⁶ CFU/fish (Fig. 1A). Subsequently, we explored specific doses within the E.coli injection range of 1 × 10² to 1 × 10⁴ CFU/fish to align with the mortality rates of sepsis in clinical practice. (A) Mortality rate 48 h after intraperitoneal microinjection of E.coli suspensions containing 1 × 10² to 1 × 10⁶ CFU into zebrafish (n = 30); (B) Statistics regarding intestinal peristalsis frequency in zebrafish 48 h after the intraperitoneal injection of E.coli suspensions containing 1 × 10² to 1 × 10⁴ CFU (The yellow dashed line indicates the intestine of zebrafish. One complete peristaltic wave from the foregut to the hindgut was counted as one event. Total peristaltic waves were recorded within two minutes) (n = 10, *p < 0.05, ****p < 0.0001); (C) The number of neutrophils in the intestine of zebrafish 6 h after the intraperitoneal injection of E.coli suspensions containing 1 × 10² to 1 × 10⁴ CFU (The yellow dashed box indicates the area where neutrophils in zebrafish intestine were counted) (n = 10, ****p < 0.0001) We selected intestinal peristalsis frequency as one of our research objectives to explore zebrafish sepsis modeling. After 48 h, the average intestinal peristalsis frequency per zebrafish was 7.9 times in the control group, 6.5 times at an E.coli dose of 1 × 10² CFU/fish, 4.9 times at an E.coli dose of 1 × 10³ CFU/fish, and 4 times at an E.coli dose of 1 × 10⁴ CFU/fish. Concurrently, we measured neutrophil infiltration in the zebrafish intestine at different doses of E.coli. The average number of intestinal neutrophils per zebrafish was 3.9 in the control group. In the E.coli groups, the average number of intestinal neutrophils per zebrafish was 18.4 in the 1 × 10² CFU/fish group, 25.1 in the 1 × 10³ CFU/fish group, and 27.9 in the 1 × 10⁴ CFU/fish group (Fig. 1C). Based on the combined assessment of mortality, intestinal motility frequency, and intestinal neutrophil counts, 1 × 10⁴ CFU/fish of E.coli was administered via intraperitoneal microinjection to establish septicemia in zebrafish. The effects of AHR ligand FICZ on sepsis in zebrafish To investigate the efficacy of indoleacetaldehyde in improving intestinal dysmotility subsequent to sepsis, we added indoleacetaldehyde to the rearing water of sepsis-modeled zebrafish. However, indoleacetaldehyde is an unstable compound that readily degrades or oxidizes under light exposure [26], making it unsuitable for addition to zebrafish rearing water for subsequent studies. Therefore, we selected 6-formylindolo[3,2-b]carbazole (FICZ), another tryptophan-derived indole compound, as a substitute for indoleacetaldehyde. FICZ is a potent endogenous activator of AHR. Carbazole (6-formylindolo[3,2-b]carbazole, FICZ) is an alternative to indoleacetaldehyde. This compound is a potent endogenous AHR agonist, more stable than indoleacetaldehyde. It effectively activates AHR1a, AHR1b, and AHR2 receptors in zebrafish [27, 28]. Moreover, within the gut, indoleacetaldehyde—produced from tryptophan metabolised by the gut microbiota—is equally unstable. Under the influence of certain enzymes, indoleacetaldehyde can serve as a precursor substance and be converted into FICZ [29]. The concentrations of 3.91 µM, 7.81 µM, 15.6 µM, 31.2 µM, and 62.5 µM were assessed to determine the maximal tolerable concentration (MTC) of FICZ. The study revealed that at FICZ concentrations of 31.2 µM and 62.5 µM, zebrafish exhibited diminished spontaneous locomotion and reduced touch responses, with these effects becoming more pronounced at higher FICZ concentrations. Concurrently, mortality began to occur at these concentrations, particularly at 62.5 µM where a 7% mortality rate was observed. Additionally, when the FICZ concentration reached 31.2 µM and 62.5 µM, crystallisation occurred in the zebrafish aquarium water due to excessive concentration. Therefore, in subsequent experiments, we employed FICZ concentrations of 3.91 µM, 7.81 µM, and 15.6 µM. The experiment comprised five groups: control, sepsis, sepsis + FICZ 3.91 µM, sepsis + FICZ 7.81 µM, and sepsis + FICZ 15.6 µM groups. The average neutrophil counts in the intestines of zebrafish were 5 cells/fish in the control group, while 31.3 cells/fish in the sepsis group, a 5.26-fold increase compared to the control group (Fig. 2A). The sepsis + FICZ 3.91 µM group, sepsis + FICZ 7.81 µM group, and sepsis + FICZ 15.6 µM group showed 13.5 cells/fish, 11.5 cells/fish, and 6.8 cells/fish, respectively, exhibiting 56.8%, 63.2%, and 78.3% decrease compared to the sepsis group. These findings indicate that administering FICZ to septic zebrafish significantly ameliorates neutrophil infiltration in the intestinal tract. (A) Intestinal neutrophil counts in zebrafish from the control, sepsis, and sepsis + FICZ groups; (B) The fluorescence intensity of intestinal smooth muscle in zebrafish from the control, sepsis, and sepsis + FICZ groups; (C) Intestinal peristalsis frequency in zebrafish in the control group, sepsis group, and sepsis + FICZ group; (D) Histopathological sections of zebrafish intestines in the control, sepsis, and sepsis + FICZ groups. Red dashed boxes outline the observed zebrafish intestines; red arrows indicate intestinal folds, and black arrows indicate intestinal villi. (n = 10, ns-no significant difference, **p < 0.01, ***p < 0.001, ****p < 0.0001) Next, we measured the changes in intestinal peristalsis frequency in zebrafish (Fig. 2C). The control group exhibited an average intestinal peristalsis frequency of 8.9 times/fish, while the sepsis group exhibited an average intestinal peristalsis frequency of 2.9 times/fish. The sepsis + FICZ 3.91 µM and sepsis + FICZ 7.81 µM groups had average intestinal peristalsis frequencies of 3.2 times/fish and 5.3 times/fish, respectively. Although these values showed improvement compared to the sepsis group, the differences were not statistically significant (p > 0.05). The average frequency of intestinal motility in the sepsis + FICZ 15.6 µM group was 7.9 times/fish, representing a 172% increase compared to the sepsis group. This finding indicates that administering FICZ to zebrafish in the Sepsis group significantly improved intestinal motility disorders, particularly at a FICZ concentration of 15.6 µM. Simultaneously, we employed 5 dpf smooth muscle line zebrafish for sepsis modeling and intervention with FICZ to detect changes in intestinal smooth muscle intensity (Fig. 2B). The average fluorescence intensity of intestinal smooth muscle was 139,216.706 pixels/fish in the control group and 97,335.529 pixels/fish in the sepsis group, representing a 30% decrease compared to the control group. Following administering FICZ, the average fluorescence intensity of intestinal smooth muscle was 119,911.163 pixels/fish in the sepsis + FICZ 3.91 µM group, showing an improvement compared to the sepsis group, although the difference between the two groups was not statistically significant (p > 0.05). The fluorescence intensities of intestinal smooth muscle were 131,837.881 pixels/fish tail and 188,681.804 pixels/fish in the sepsis + FICZ 7.81 µM and sepsis + FICZ 15.6 µM groups, respectively. They exhibited increases of 35.4% and 93.8% compared to the sepsis group. These findings suggest that administering FICZ to septic zebrafish improves intestinal smooth muscle strength. We also analyzed the folds and villi in the intestines of zebrafish in all groups. Pathological sections of zebrafish intestines showed that the number of folds and villi in the intestines of the sepsis group was significantly reduced compared to the control group (Fig. 2D). After administering FICZ to the sepsis group, the intestinal folds and villi in the sepsis + FICZ group showed marked improvement compared to the untreated sepsis group. This effect was more pronounced at higher FICZ concentrations. At 15.6 µM FICZ, the intestinal folds and villi in the sepsis + FICZ group became comparable to those in the control group. Next, we analyzed the changes in the expression levels of AHR1a, AHR2, CYP1A, and TRPA1b genes, as well as inflammatory genes IL-6, TNF-α, and IL-1β in the zebrafish intestine. Compared to the control group, the expression levels of AHR1a and AHR2 genes in the zebrafish intestine decreased by approximately 240% and 250% in sepsis, respectively. In the sepsis + FICZ group, at FICZ concentrations of 3.91 µM and 7.81 µM, the expression levels of AHR1a and AHR2 genes showed a slight increase compared to the sepsis group, but the difference was not statistically significant. When the concentration of FICZ was increased to 15.6 µM, AHR1a gene expression increased by 258% and AHR2 gene expression increased by 179% (Fig. 3B-C). (A-G) Gene expression levels of CYP1A, AHR1a, AHR2, TRPA1b, IL-6, TNF-α, and IL-1β in the intestines of zebrafish from the control, sepsis, and sepsis + FICZ groups (n = 3, ns-p > 0.05, * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) We measured the expression levels of CYP1A(Cytochrome P450, family 1, subfamily A, polypeptide 1), a target gene of the AHR family, to confirm that the increased expression levels of the AHR family genes in the intestines of the sepsis + FICZ group were caused by the activation of the AHR ligand FICZ. The expression levels of the CYP1A gene are commonly measured to detect AHR receptor activation. Compared to the control group, CYP1A expression in the zebrafish gut decreased by approximately 227% during sepsis, suggesting reduced AHR receptor activation. In the sepsis + FICZ group, CYP1A expression increased more than 100-fold across all three groups of zebrafish (Fig. 3A). Additionally, we measured the expression levels of the TRPA1b gene in zebrafish intestines. During sepsis, TRPA1b gene expression in zebrafish intestines was downregulated by approximately 30-fold compared to the control group. In the sepsis + FICZ group, the expression level of the TRPA1b gene in the 3.91 µM group showed no significant difference compared to the sepsis group. However, compared to the sepsis group, the 7.81 µM and 15.6 µM groups exhibited increases of approximately 236% and 266%, respectively (Fig. 3D). These results suggest that during sepsis, low expression of AHR family genes in the zebrafish intestine is correlated with decreased TRPA1b gene expression. Simultaneously, we measured the changes in the expression levels of inflammatory genes IL-6, TNF-α, and IL-1β in the zebrafish intestine (Fig. 3E-G). Compared to the control group, the expression levels of IL-6, TNF-α, and IL-1β genes were significantly reduced in the sepsis group, contrary to the commonly observed increase in inflammatory gene expression 6 h after sepsis modeling. This reduction may originate from immunosuppression after sepsis. In the sepsis + FICZ group, at FICZ concentrations of 3.91 µM and 7.81 µM, the expression levels of IL-6, TNF-α, and IL-1β increased compared to the sepsis group, and at 7.81 µM, they became closer to the control group. This finding suggests that FICZ concentrations of 3.91 µM and 7.81 µM can improve the immunosuppressive state after zebrafish sepsis. However, at a FICZ concentration of 15.6 µM, the expression levels of IL-6, TNF-α, and IL-1β were higher than those of the control group, suggesting that FICZ may exert a pro-inflammatory effect on septic zebrafish at this concentration. To elucidate the effects of FICZ, we examined the impact of FICZ concentrations of 3.91 µM, 7.81 µM, and 15.6 µM on 5-day-post-fertilisation (dpf) zebrafish under physiological conditions. Results demonstrated that 7.81 µM and 15.6 µM FICZ mildly increased intestinal motility in zebrafish (Fig. 4 A), with concomitant elevations in AHR1a, AHR2, and TRPA1b gene expression levels within the intestinal tract at these concentrations (Fig. 4 C, D, F). CYP1A gene expression levels in the intestines of all FICZ-treated zebrafish increased more than 100-fold compared to the control group (Fig. 4E). This finding suggests that FICZ at concentrations of 7.81 µM and 15.6 µM may enhance intestinal motility in physiological conditions via the AHR-TRPA1b pathway. Although all three FICZ concentrations increased neutrophil counts in zebrafish intestines (Fig. 4B) and elevated expression levels of inflammatory genes IL-6, TNF-α, and IL-1β (Fig. 4G-I), these changes did not reach statistical significance. The increase in inflammatory factor levels may result from reactive oxygen species (ROS) generated by CYP1A metabolism of FICZ; however, this level of ROS is insufficient to alter the internal homeostasis of zebrafish. Effects of FICZ on physiological conditions in 5 dpf zebrafish. Control group and FICZ 3.91 μM, 7.81 μM, 15.6 μM groups;(A) Intestinal peristalsis frequency; (B) Intestinal neutrophil count; (C-I) Gene expression levels of AHR1a, AHR2, CYP1A, TRPA1, IL-6, TNF-α, and IL-1β in in the intestines of zebrafish;(n=3/n=20, ns-p>0.05, * p< 0.05, **p< 0.01, ***p< 0.001,****p<0.0001) The effects of AHR gene overexpression in pan-neuronal cells on septic zebrafish We injected Tol-huc-AHR1a overexpression plasmids and TP transposase mixture (25.0 ng/µL) into zebrafish embryos to generate the pan-neuronal AHR1a-overexpressing (AHR1a OE) zebrafish and investigate the role of the AHR gene in intestinal motility disorders during sepsis. The Huc promoter is a pan-neuronal-specific promoter that has been extensively utilised and thoroughly validated in zebrafish research. It specifically drives the expression of downstream genes (in our experiments, AHR1a) in all differentiated neurons within the zebrafish. Sepsis models were established using AHR1a OE zebrafish from different strains to analyze the effects of AHR1a overexpression on septic zebrafish. The average number of intestinal contractions in the sepsis group was 3.1 contractions per fish, significantly lower than that in the control group (7.9 contractions per fish). However, the AHR1a OE group exhibited an average of 7.1 contractions per fish, which was similar to that observed in the control group (Fig. 5A), suggesting that AHR1a OE can improve intestinal motility disorders in septic zebrafish. (A) Intestinal peristalsis frequency in zebrafish in the control, sepsis, and sepsis + AHR1a OE groups; (B) Neutrophil infiltration in the intestines of zebrafish in the control, sepsis, and sepsis + AHR1a OE groups; (C) NO levels in the intestines of zebrafish in the control, sepsis, and sepsis + AHR1a OE groups (yellow dashed box indicates the region where NO levels in the zebrafish intestine were quantified); (n = 10, ****p < 0.0001) The average number of neutrophils in the intestines of zebrafish was 34.4 per fish in the sepsis group, representing a 4.14-fold increase compared to that observed in the control group (6.7 per fish). However, the AHR1a OE group exhibited an average of 15.1 neutrophils per fish, suggesting a 56.1% decrease compared to the sepsis group (Fig. 5B). This suggests that AHR1a OE ameliorated intestinal neutrophil infiltration in septic zebrafish. We also measured the production of the inhibitory neurotransmitter NO in zebrafish intestines. The average fluorescence intensity of NO in the intestines of the sepsis group was 1,202,982.928 pixels/fish, representing 46% increase compared to that detected in the control group (821,640.2353 pixels/fish). This finding correlates with the reduced intestinal motility observed in the sepsis group. The average fluorescence intensity of NO in the intestines of AHR1a OE zebrafish was 822,495.1765 pixels/fish, which was similar to that detected in the control group level (Fig. 5C). This finding, along with the restoration of intestinal peristalsis frequency in the AHR1a OE group, suggests that AHR1a OE improves intestinal motility disorders in septicemic zebrafish by reducing NO levels in the intestine. Next, we evaluated the expression levels of AHR1a, TRPA1b, and inflammatory genes IL-6, TNF-α, and IL-1β in the zebrafish intestine. In the sepsis group, the intestinal expression of AHR1a and TRPA1b genes was reduced compared to the control group (Fig. 6A-B). However, in the AHR1a OE group, the intestinal expression of TRPA1b was significantly increased compared to the sepsis group, recovering to 81% of control levels (Fig. 6B). Regarding inflammatory genes, the expression levels of IL-6, TNF-α, and IL-1β were significantly reduced in the intestines of the sepsis group (Fig. 6C-E), suggesting that these zebrafish were in an immunosuppression state. However, the expression levels of IL-6、TNF-α and IL-1β in the AHR1a OE group were markedly elevated compared to the sepsis group and were close to IL-6、TNF-α and IL-1β levels in the control group (Fig. 6C-E). This finding suggests that AHR1a OE can improve immunosuppression in septic zebrafish. (A–E) Expression levels of AHR1a, TRPA1b, IL-6, TNF-α, and IL-1β genes in the intestines of zebrafish from the control group, sepsis group, and sepsis + AHR1a OE group (48 h after sepsis modeling); (n = 3, * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) Discussion The regulation of ENS plays a crucial role in the intestinal motility disorders induced by sepsis, yet the specific regulatory mechanisms remain largely unknown. In this study, we observed that in zebrafish exhibiting sepsis-induced intestinal motility disorders, there was a significant reduction in the expression of AHR and TRPA1 genes within the intestine, concurrent with an increase in the inhibitory neurotransmitter NO within the zebrafish gut. AHR ligand FICZ and overexpression of the AHR gene in ENS reversed these findings while also ameliorating the immunosuppressive state induced by sepsis. The AHR on the ENS plays a crucial role in intestinal motility. The ENS primarily regulating intestinal motility is the myenteric plexus of the longitudinal muscles, which influences intestinal movement by modulating neurotransmitter release, intestinal smooth muscle activity, and intestinal immune function [30–32]. Research indicates that tryptophan metabolites produced by gut microbiota can influence AHR receptor regulation of intestinal motility via the myenteric plexus, achieved by modulating the inwardly rectifying potassium channel Kir2.2, which is also located on the ENS [16]. Our earlier analysis of gut microbial metabolite alterations in faecal samples from clinical sepsis patients revealed that reduced intestinal AHR expression, caused by decreased indoleacetaldehyde levels, contributes to dysmotility in sepsis [10]. Unlike Obata et al., our subsequent research focused specifically on TRPA1, which is also located on ENS neurons. Our study revealed that AHR regulation of TRPA1 within the ENS influences the contractile strength of zebrafish intestinal smooth muscle, potentially via modulation of TRPA1 Ca²⁺ transport. Within the ENS, TRPA1 colocalises with nitrergic neurons, and application of TRPA1 agonists and antagonists to isolated colon segments alters colonic NO levels, thereby affecting peristalsis [18]. In a zebrafish model of sepsis-induced intestinal motility disorders, synchronous reductions in both AHR and TRPA1 levels were observed in the intestine. This effect was reversed by the AHR ligand FICZ and by AHR1a OE in the ENS, suggesting a regulatory mechanism for TRPA1 mediated by ENS-bound AHR. However, the precise mechanism by which ENS AHR regulates TRPA1 remains unclear. Phosphatidylinositol 4,5-bisphosphate (PIP₂), crucial for maintaining the functional conformation of TRPA1 [33], undergoes extensive hydrolysis under the oxidative stress conditions of sepsis. This may cause PIP₂ to dissociate from its binding site on TRPA1, leading to channel inactivation or desensitisation. Additionally, cellular oxidative stress can influence the channel state of TRPA1 [18]. AHR has been demonstrated to regulate oxidative stress via downstream STAT3 and Nrf2 pathways [34, 35]. AHR on the ENS may modulate TRPA1 by mediating cellular oxidative stress responses, though this conclusion requires further experimental validation. Research indicates that the tryptophan metabolic pathway IDO1-Kyn-AHR is involved in immune suppression during the late phase of sepsis. During the immunosuppressive phase of sepsis, the innate immune system responds to inflammatory signals generated in the early phase (such as IFN-γ and TNF-α) by substantially upregulating an enzyme—IDO1 (Indoleamine 2,3-dioxygenase 1). Upon activation, IDO1 initiates the catabolic breakdown of tryptophan, converting it into kynurenine (Kyn) and its downstream metabolites [36]. Kyn binds to the aryl hydrocarbon receptor (AHR) on immune cells, inducing a state of ‘paralysis’. The specific mechanisms are as follows: (i) promoting macrophage polarisation towards the anti-inflammatory M2 phenotype rather than the pro-inflammatory M1 type [37]; (ii) shifting dendritic cell phenotypes from ‘pro-inflammatory’ to ‘tolerogenic’ [38]; (iii) suppressing natural killer (NK) cell-mediated cytotoxicity [39]. FICZ is currently recognised as one of the highest-affinity endogenous AHR ligands, whilst kynanidine is considered a weak AHR agonist. Owing to this substantial affinity disparity, FICZ predominantly occupies the AHR ligand-binding domain under most physiological or experimental conditions. As the adaptive immune system remains immature in 5 dpf zebrafish, all effects of FICZ on their immune system are mediated through the innate immune system. Research indicates that FICZ promotes the differentiation of M1 macrophages, which exhibit pro-inflammatory and immune-activating properties [40]. Reactivated and differentiated M1 macrophages phagocytose pathogens that have translocated through the intestinal endocytic barrier following its disruption, a process generating substantial quantities of inflammatory cytokines. FICZ also serves as a substrate for CYP1A1 (an AHR target gene), and its metabolism via a mitochondrial-dependent pathway induces oxidative stress and increased ROS production [41]. Following administration of the AHR agonist FICZ, TRPA1 levels and function are restored, allowing Na⁺ and Ca²⁺ influx into cells and inducing marked membrane depolarisation. To counteract this depolarisation and restore membrane potential, cells must open their voltage-gated potassium channels, resulting in substantial potassium (K⁺) efflux. This K⁺ efflux and increased ROS may also serve as a secondary signal to reactivate NLRP3 oligomerisation and Caspase-1 activation, interrupted by macrophage immunosuppression, thereby cleaving Pro-IL-1β into mature, active IL-1β [42]. In this context, FICZ functions as a ‘homeostatic restorer’, preventing innate immune cells (such as macrophages) from entering “exhaustion” and ‘paralysis’ states. This enables immune cells to maintain their functionality and persistently clear pathogens from the organism. Consequently, the elevated inflammatory cytokine levels observed in zebrafish at this stage are not attributable to a ‘pro-inflammatory effect’ driven by FICZ’s pharmacological properties. Rather, they are more likely a ‘side effect’ of the sustained innate immune system’s pathogen clearance. This interpretation is corroborated by the restoration of the intestinal barrier, the resumption of intestinal motility, and the reduction in intestinal neutrophil infiltration. In inflammation-induced intestinal barrier damage, the ligand FICZ activates the aryl hydrocarbon receptor (AHR) on type 3 innate lymphoid cells (ILC3s) within the intestinal barrier, thereby inducing IL-22 production. IL-22 exerts potent restorative and protective effects on the intestinal barrier, including: promoting epithelial cell proliferation and migration to repair damage; enhancing tight junction protein expression to restore the intestinal barrier; and inducing antimicrobial peptide production to regulate the local microbiota [43]. This aligns with our findings showing improved intestinal villi and folds in septic zebrafish following FICZ administration. FICZ further activates AHR in intestinal endothelial cells, reducing the secretion of adhesion molecules and chemokines by inhibiting nuclear transcription of NF-κB p65 [44]. The reduction in adhesion molecule and chemokine secretion within intestinal epithelial cells, coupled with diminished migration of neutrophils to the gut, results from barrier repair. Consequently, the decrease in intestinal neutrophil infiltration is more likely attributable to the potent reparative effects of AHR activation within the intestinal barrier. Research findings indicate that the effect of AHR1a overexpression (OE) in enteric neurons during sepsis mirrors that of FICZ, though their mechanisms may differ. AHR on the enteric nervous system (ENS) can co-express with both acetylcholine-ergic and 5-HT-ergic neurons [45, 46]. AHR1a OE promotes the release of 5-HT and acetylcholine (Ach) from these neurons, thereby influencing macrophage immune activity. 5-HT promotes macrophage differentiation towards both M1 and M2 phenotypes, conferring dual anti-inflammatory and pro-inflammatory functions [47]; Ach activates the macrophage ‘cholinergic anti-inflammatory pathway’ to exert anti-inflammatory effects [48]. Prior to sepsis modelling, AHR1a OE regulates the epigenetic and metabolic states of innate immune cells, maintaining them in a persistent ‘combat state’ that prevents immunosuppression. Consequently, in AHR1a OE zebrafish, although E. coli induced an initial ‘cytokine storm,’ the persistently activated innate immune system continuously exerted anti-inflammatory effects from the outset. This mitigated intestinal injury, reduced intestinal chemokine levels, and diminished neutrophil infiltration in the gut. Concurrently, this persistent innate immune engagement prevented the zebrafish from entering the immunosuppressive phase characteristic of late-stage sepsis. By 48 h post-infection, harmful pathogens such as E. coli and LPS were nearly eradicated, with overall inflammatory cytokine levels returning to those observed in the control group. Although cytokine levels remained elevated compared to the sepsis group, this increase reflects the active engagement of the immune system. Research indicates that AHR and its ligands exhibit biphasic effects, both pro-inflammatory and anti-inflammatory. Potential reasons for this outcome include: (i) differences in ligand properties; (ii) variations in cell types expressing AHR; and (iii) differences in co-activators present within AHR-expressing cells [49]. Consequently, within tissues, both ligands and intrinsic cellular factors will determine the outcome of AHR activation. Our findings demonstrate that during sepsis, the ENS can improve intestinal motility via the AHR/TRPA1 pathway, whilst AHR and its ligands may also ameliorate sepsis-induced immunosuppression. AHR has been shown to repair inflammation-damaged intestinal barriers by participating in multiple immune responses [50], and certain tryptophan derivatives produced by the gut microbiota—acting as AHR ligands—have demonstrated efficacy in inflammatory bowel disease [51]. Consequently, AHR on the ENS may represent a future therapeutic target for ameliorating sepsis-induced immunosuppression and treating intestinal motility disorders in sepsis; however, this requires confirmation through more comprehensive and systematic experimental studies. At the time, our research also had certain limitations. Firstly, although 5dpf zebrafish represent an ideal model for studying sepsis immunity due to their innate immune system, the small size of the fish and the difficulty of handling them meant that we were unable to isolate the intestinal myenteric plexus for in vitro experimental validation in this study. Secondly, the mechanism by which AHR regulates TRPA1 in the ENS remains unclear. Genomic sequencing of ENS cells or tissues may elucidate the underlying mechanisms. We plan to conduct further studies using gene editing and fluorescent labelling on primary mouse myenteric neurons to uncover the deeper mechanisms by which the AHR-TRPA1 axis in the ENS causes intestinal motility disorders during sepsis. Acknowledgements Not applicable. Clinical trial number Not applicable. Abbreviations 6-formylindolo[3,2-b]carbazole Enteric Nervous System Aryl hydrocarbon receptor basic helix-loop-helix Xenobiotic Response Element Longitudinal Muscle Myenteric Plexus Transient Receptor Potential Ankyrin 1 Nitric Oxide Tumor Necrosis Factor-α Interleukin-1β Interleukin-6 Maximal Tolerable Concentration Cytochrome P450, family 1, subfamily A, polypeptide 1 Aryl hydrocarbon receptor 1a Aryl hydrocarbon receptor 2 Generate Aryl hydrocarbon receptor 1a-overexpressing Inward-rectifier potassium (K+) channels 2.2 Authors’ contributions All authors contributed to the study conception and design. **Jingtao Zhang** : Writing – review & editing, Writing – original draft, Formal analysis, Data curation, Conceptualization. **Ziang Li** : Formal analysis, Data curation. **Tong Jin** : Formal analysis, Conceptualization. **Wanglin Zhang** : Writing – review & editing, Conceptualization. **Hongwei Shi** : Formal analysis, Data curation. **Kanlirong Wang** : Writing – original draft, Data curation. **Jiayi Qi** : Writing – original draft, Formal analysis. Conceptualization. **Liqun Sun** : Writing – review & editing, Writing – original draft, Formal analysis, Conceptualization. All authors read and approved the final manuscript. Funding This study was supported by Scientific research project of Jiangsu Provincial Health Commission [LR2022003]. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nanjing Medical University (IACUC-2409071). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jintao Zhang, Ziang Li and Tong Jin co-first authors, contributed equally to this work. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.